Predictive Biomarkers Market Outlook Through 2030: Understanding The Growth Opportunity
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Predictive Biomarkers Market Revenue Growth On Track For A 4% CAGR Through 2030
The predictive biomarkers market has experienced consistent expansion in recent years. It is anticipated to increase from $20.96 billion in 2025 to $21.88 billion in 2026, progressing at a compound annual growth rate (CAGR) of 4.4%. The historical growth of this market can be ascribed to factors like growth in genomic research, rise in targeted therapies, increasing cancer prevalence, expansion of molecular diagnostics, and regulatory support for biomarkers.
The predictive biomarkers market is projected to experience consistent expansion in the coming years. It is anticipated to reach $25.65 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 4.0%. This growth during the forecast period is driven by factors such as progress in multi-omics technologies, the broadening scope of personalized medicine, increased pharmaceutical research and development expenditure, the need for predictive treatment results, and the incorporation of biomarkers into standard healthcare practices. Key developments expected over the forecast horizon involve the wider application of precision oncology, an increase in their utility for drug response stratification, more biomarker-driven clinical trial designs, the growing uptake of companion diagnostics, and the establishment of standardized biomarker validation protocols.
Get A Free Sample Report With In-Depth Market Insights:
Predictive Biomarkers Market Growth Drivers: What’s Behind The Acceleration?
The increasing incidence of cancer is anticipated to fuel the expansion of the predictive biomarkers market moving ahead. Cancer is defined by the uncontrolled proliferation of cells, which have the capacity to invade and metastasize to other bodily regions. This surge in cancer cases stems mainly from an aging global demographic, evolving lifestyle habits, and heightened exposure to risk elements like tobacco, poor dietary choices, and environmental contaminants. Within oncology, predictive biomarkers are instrumental in pinpointing patients who are probable candidates for particular treatments, thus facilitating personalized and more efficacious therapeutic strategies. For example, a report from April 2024 by the International Agency for Research in Cancer (IARC), a specialized France-based World Health Organization (WHO) agency dedicated to cancer research, indicated that 2022 saw nearly 20 million new cancer diagnoses and approximately 10 million deaths attributed to cancer. Furthermore, forecasts indicate that the yearly count of new cancer cases is set to escalate to 35 million by 2050, signifying a 77% increase compared to 2022 figures. Consequently, the escalating number of cancer cases is poised to propel the predictive biomarkers market’s growth.
Predictive Biomarkers Market Segment Analysis Spotlighting Growth Areas
The predictive biomarkers market covered in this report is segmented –
1) By Indication: Cancer, Metabolic Disease, Cardiovascular Disorder, Immunological Disorder, Other Indications
2) By Application: Screening, Analysis, Diagnosis, Prediction, Monitoring
3) By End User: Diagnostic Centers, Contract Research Organizations, Academic Research Institutes, Pharms And Biotech Companies, Other End Users
Subsegments:
1) By Cancer: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Leukemia And Lymphoma, Melanoma, Pancreatic Cancer, Kidney Cancer, Head And Neck Cancer
2) By Metabolic Disease: Type 1 And Type 2 Diabetes, Obesity, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease (NAFLD), Dyslipidemia, Insulin Resistance
3) By Cardiovascular Disorder: Atherosclerosis, Coronary Artery Disease, Heart Failure, Myocardial Infarction (Heart Attack), Arrhythmia, Hypertension, Stroke, Peripheral Arterial Disease
4) By Immunological Disorder: Autoimmune Diseases, Inflammatory Bowel Disease (Ibd), Multiple Sclerosis, Psoriasis, Allergic Diseases, Asthma, Chronic Obstructive Pulmonary Disease (Copd), Immunodeficiency Disorders
5) By Other Indications: Neurological Disorders, Infectious Diseases, Renal Diseases, Osteoarthritis, Genetic Disorders, Respiratory Disorders
Predictive Biomarkers Market Trends: What’s Defining The Industry’s Next Phase?
Leading firms within the predictive biomarkers market are prioritizing the speed of biomarker development, leveraging technological progress such as artificial intelligence (AI)-driven biomarker discovery. This strategy aims to secure a competitive advantage by delivering more tailored and potent treatments at an accelerated pace. Through AI-driven biomarker discovery, extensive and intricate datasets can be analyzed, uncovering predictive biomarkers that traditional approaches might miss. An illustration of this is the July 2024 launch by Scipher Medicine, Inc., a precision immunology company based in the US, of their PRoBeNet (Predictive Response Biomarkers using Network Medicine). The objective of PRoBeNet is to hasten the creation of predictive response biomarkers for intricate diseases, utilizing AI and network biology. It functions by pinpointing therapy response biomarkers through the combination of therapy-targeted proteins and distinct molecular signatures associated with diseases. Validated for autoimmune conditions like rheumatoid arthritis, ulcerative colitis, and Crohn’s disease, its application extends to additional complex diseases and various stages of drug development.
Predictive Biomarkers Market Top Companies Driving Competitive Growth
Major companies operating in the predictive biomarkers market are Johnson & Johnson Services Inc, F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthcare GmbH, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories Inc, QIAGEN GmbH, Almac Group Limited, ArcherDX Inc, Luminex Corporation, Guardant Health Inc, Meso Scale Diagnostics LLC, Myriad Genetics Inc, NanoString Technologies Inc, Fujirebio Inc, Asuragen Inc, Biognosys AG, Epigenomics AG, OncoCyte Corporation, Biomarker Technologies Inc
View The Full Predictive Biomarkers Market Report:
Predictive Biomarkers Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the predictive biomarkers market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
